NCT07209111 2026-04-13
KANDLELIT-014
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05217069 2025-04-16
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT02316496 2017-08-01
REGAIN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Terminated
NCT00226239 2017-07-11
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT02014831 2016-02-25
PENILANE
Centre Leon Berard
Phase 2 Withdrawn
NCT00439517 2014-06-27
FUTURE
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT01216345 2010-10-07
Cetuximab + Gemox in Biliary Tract Cancer
Association of Research on the Biology of Liver Tumors
Phase 2 Completed
NCT00894569 2009-05-14
PACET-CUP
Heidelberg University
Phase 2 Unknown